{
  "symbol": "KZIA",
  "company_name": "Kazia Therapeutics Ltd ADR",
  "ir_website": "https://www.kaziatherapeutics.com/site/for-investors",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://www.kaziatherapeutics.com/site/for-investors/press-releases",
          "content": "![](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n[![Kazia Therapeutics Limited](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)](/)\n\nHeading &\n\nSub-heading can be edited through HQI \n\n[ Home](/site/content/default.aspx) / [ For Investors](/site/for-investors) /[ Press Releases](/site/for-investors/press-releases)\n\n[](javascript:window.print\\(\\) \"Print Page\") [](# \"Font Smaller\") [](# \"Font Larger\")\n\n  * [Press Releases](/site/for-investors/press-releases)\n  * [ASX Announcements](/site/for-investors/asx-announcements)\n  * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n    * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n  * [SEC Filings](/site/for-investors/sec-filings)\n  * [Corporate Presentations](/site/for-investors/corporate-presentations)\n  * [Annual Reports](/site/for-investors/annual-reports)\n  * [ Financial Reports](/site/for-investors/financial-reports)\n  * [AGM](/site/for-investors/agm)\n  * [Corporate Governance](/site/for-investors/corporate-governance)\n  * [Shareholder Services](/site/for-investors/shareholder-services)\n\n\n\n# Press Releases\n\nFilter by Year:[2024](/site/for-investors/press-releases?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2024) [2023](/site/for-investors/press-releases?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2023)\n\n4-Nov-2024\n\n[Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme](https://www.kaziatherapeutics.com:443/site/pdf/9fa4330b-ea3d-4019-8d33-ece30d49cd66/Kazia-Therapeutics-Announces-Granting-of-Type-C-Meeting-with-FDA-to-Discuss-Potential-Next-Steps-for-Paxalisib-in-the-Treatment-of-Newly-Diagnosed-Glioblastoma-Multiforme.pdf)\n\n2-Oct-2024\n\n[ Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy at the American Society for Radiation Oncology 66th Annual Meeting](https://www.kaziatherapeutics.com:443/site/pdf/0c3ffa0f-154b-49db-a6ae-5b0dbf83704f/Kazia-Therapeutics-Announces-Presentation-of-Promising-Phase-I-Data-Evaluating-Concurrent-Paxalisib-and-Radiation-Therapy-at-the-American-Society-for-Radiation-Oncology-66th-Annual-Meeting.pdf)\n\n23-Sep-2024\n\n[Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium](https://www.kaziatherapeutics.com:443/site/pdf/c97cac8d-8cfd-48e8-9363-9f20b404e1e8/Kazia-Therapeutics-Announces-Presentation-of-EVT801-Clinical-Data-at-15th-Biennial-Ovarian-Cancer-Research-Symposium.pdf)\n\n12-Sep-2024\n\n[Kazia Executes Licensing Agreement with QIMR Berghofer](https://www.kaziatherapeutics.com:443/site/pdf/01edb80c-8be1-4e2f-9044-4704dbbbee21/Kazia-Executes-Licensing-Agreement-with-QIMR-Berghofer.pdf)\n\n10-Jul-2024\n\n[Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma](https://www.kaziatherapeutics.com:443/site/pdf/be0e3a1c-e12c-44f4-bf3f-2d79f8829cf8/Kazia-Therapeutics-Announces-Phase-IIIII-Clinical-Trial-Results-for-Paxalisib-in-Glioblastoma.pdf)\n\n27-Jun-2024\n\n[Kazia Announces Upcoming DIPG Data Presentations at ISPNO And Publication in European Journal of Cancer](https://www.kaziatherapeutics.com:443/site/pdf/6227c640-2eae-4bcb-9423-bcca33ac5bfb/Kazia-Announces-Upcoming-DIPG-Data-Presentations-at-ISPNO-And-Publication-in-European-Journal-of-Cancer.pdf)\n\n2-May-2024\n\n[Kazia Reports Successful Stage 1 Completion Of The Evt801 Phase 1 Clinical Trial In Advanced Cancer Patients](https://www.kaziatherapeutics.com:443/site/pdf/4489c699-d8f3-469e-a722-15aa2b424141/Kazia-Reports-Successful-Stage-1-Completion-Of-The-Evt801-Phase-1-Clinical-Trial-In-Advanced-Cancer-Patients.pdf)\n\n21-Mar-2024\n\n[Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases](https://www.kaziatherapeutics.com:443/site/pdf/d7dc93eb-e5ae-4792-998e-a8157f69b980/Kazia-Therapeutics-licenses-paxalisib-to-Sovargen-for-intractable-seizures-in-rare-central-nervous-system-diseases.pdf)\n\n14-Mar-2024\n\n[Kazia announces presentation of new data at AACR Annual Meeting](https://www.kaziatherapeutics.com:443/site/pdf/876fbdd9-abbe-46f2-8c1a-0e55201bee8d/Kazia-announces-presentation-of-new-data-at-AACR-Annual-Meeting.pdf)\n\n21-Feb-2024\n\n[Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint](https://www.kaziatherapeutics.com:443/site/pdf/7896c9b7-bcf0-45c0-bcb0-2d32dae80c3b/Kazia-Therapeutics-Reports-Early-Conclusion-of-Clinical-Trial-After-Reaching-Primary-Endpoint.pdf)\n\n  * 1\n  * [2](/site/for-investors/press-releases?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=2)\n  * [ Next](/site/for-investors/press-releases?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=2)\n\n\n\n### Quick Links\n\n[Home](/site/content/)[About Us](/site/about-us1)[For Researchers](/site/for-researchers)[For Partners](/site/for-partners)[For Patients](/site/for-patients)[For Investors](/site/for-investors)[Media Centre](/site/media-centre)[Contact](/site/contact)\n\n### Contact Us\n\n**Kazia Therapeutics Limited** Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia  info@kaziatherapeutics.com [ https://www.kaziatherapeutics.com](https://www.kaziatherapeutics.com/)\n\n### Subscribe to Email Alerts\n\nASX Announcements\n\nMedia Releases & News\n\nWhich of the following group do you best fit?\n\nWhich of the following group do you best fit? Analyst Broker Financial Adviser Fund Manager Institutional Investor Sophisticated Investor Private Investor Media Representative General Interest\n\nYes No\n\n### Email Alerts\n\nSubscribe to our Email Alerts\n\n### Follow Us\n\n[](https://www.linkedin.com/company/kaziatx/) [](https://twitter.com/KaziaTx) [](https://www.youtube.com/channel/UCiovte4Ru7azEjm4pFaW2Xg)\n\nCopyright © 2024 Kazia Therapeutics Limited \n\n[Site Map](/site/utilities/site-map) [Privacy](/site/utilities/privacy) [Search](/site/utilities/site-map/search)\n\n[ Design byspatialdesign ](https://spatialdesign.com.au) [ Site by ![](/site/content/images/irm-logo-small-white.png) ](http://www.irmau.com)\n"
        }
      ]
    },
    {
      "section_name": "ASX Announcements",
      "links": [
        {
          "title": "ASX Announcements",
          "url": "https://www.kaziatherapeutics.com/site/for-investors/asx-announcements",
          "content": "![](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n[![Kazia Therapeutics Limited](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)](/)\n\nHeading &\n\nSub-heading can be edited through HQI \n\n[ Home](/site/content/default.aspx) / [ For Investors](/site/for-investors) /[ ASX Announcements](/site/for-investors/asx-announcements)\n\n[](javascript:window.print\\(\\) \"Print Page\") [](# \"Font Smaller\") [](# \"Font Larger\")\n\n  * [Press Releases](/site/for-investors/press-releases)\n  * [ASX Announcements](/site/for-investors/asx-announcements)\n  * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n    * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n  * [SEC Filings](/site/for-investors/sec-filings)\n  * [Corporate Presentations](/site/for-investors/corporate-presentations)\n  * [Annual Reports](/site/for-investors/annual-reports)\n  * [ Financial Reports](/site/for-investors/financial-reports)\n  * [AGM](/site/for-investors/agm)\n  * [Corporate Governance](/site/for-investors/corporate-governance)\n  * [Shareholder Services](/site/for-investors/shareholder-services)\n\n\n\n# ASX Announcements\n\nFilter by Year:[2023](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2023) [2022](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2022) [2021](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2021) [2020](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2020) [2019](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2019) [2018](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2018)\n\n15-Nov-2023\n\n[Removal from Official List](https://www.kaziatherapeutics.com/site/pdf/5b9f4cc1-448b-42d4-a6a5-3f69bad126f3/Removal-from-Official-List.pdf)\n\n14-Nov-2023\n\n[Change in substantial holding](https://www.kaziatherapeutics.com/site/pdf/10f292ea-e609-49a3-8e38-3064730b895a/Change-in-substantial-holding.pdf)\n\n13-Nov-2023\n\n[Suspension from Official List](https://www.kaziatherapeutics.com/site/pdf/f38b4d3a-06cf-4246-8706-e1b3ad65f53b/Suspension-from-Official-List.pdf)\n\n8-Nov-2023\n\n[Change in substantial holding](https://www.kaziatherapeutics.com/site/pdf/20489371-c28f-4993-83e7-caf800a60e80/Change-in-substantial-holding.pdf)\n\n3-Nov-2023\n\n[Notice of Annual General Meeting/Proxy Form](https://www.kaziatherapeutics.com/site/pdf/bb537957-d9a4-42d8-b3d4-5951374427f7/Notice-of-Annual-General-MeetingProxy-Form.pdf)\n\n2-Nov-2023\n\n[Preliminary update from ongoing Phase 2 Study of Paxalisib](https://www.kaziatherapeutics.com/site/pdf/b10cd830-5c66-456d-b107-9bf0898947ce/Preliminary-update-from-ongoing-Phase-2-Study-of-Paxalisib.pdf)\n\n31-Oct-2023\n\n[Proposed issue of securities - KZA](https://www.kaziatherapeutics.com/site/pdf/a019f65f-7b44-4e86-b5ae-4e7f040e2338/Proposed-issue-of-securities-KZA.pdf)\n\n31-Oct-2023\n\n[Kazia announces short term unsecured Promissory Note](https://www.kaziatherapeutics.com/site/pdf/be9f6756-fea0-4d6c-8fdd-b65e65553b86/Kazia-announces-short-term-unsecured-Promissory-Note.pdf)\n\n31-Oct-2023\n\n[Quarterly Activities/Appendix 4C Cash Flow Report](https://www.kaziatherapeutics.com/site/pdf/5746f521-bb62-47d5-a65a-75f0f9a5a0fa/Quarterly-ActivitiesAppendix-4C-Cash-Flow-Report.pdf)\n\n27-Oct-2023\n\n[Kazia SEC Form 20-F](https://www.kaziatherapeutics.com/site/pdf/3a31e482-3bfd-451e-a0f2-009a35c4f183/Kazia-SEC-Form-20F.pdf)\n\n  * 1\n  * [2](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=2)\n  * [3](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=3)\n  * [4](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=4)\n  * [5](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=5)\n  * [6](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=6)\n  * [7](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=7)\n  * [8](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=8)\n  * [9](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=9)\n  * [ Next](https://www.kaziatherapeutics.com/site/for-investors/asx-announcements?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&year=latestyear&month=&DisplayType=E&Page=2)\n\n\n\n### Quick Links\n\n[Home](/site/content/)[About Us](/site/about-us1)[For Researchers](/site/for-researchers)[For Partners](/site/for-partners)[For Patients](/site/for-patients)[For Investors](/site/for-investors)[Media Centre](/site/media-centre)[Contact](/site/contact)\n\n### Contact Us\n\n**Kazia Therapeutics Limited** Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia  info@kaziatherapeutics.com [ https://www.kaziatherapeutics.com](https://www.kaziatherapeutics.com/)\n\n### Subscribe to Email Alerts\n\nASX Announcements\n\nMedia Releases & News\n\nWhich of the following group do you best fit?\n\nWhich of the following group do you best fit? Analyst Broker Financial Adviser Fund Manager Institutional Investor Sophisticated Investor Private Investor Media Representative General Interest\n\nYes No\n\n### Email Alerts\n\nSubscribe to our Email Alerts\n\n### Follow Us\n\n[](https://www.linkedin.com/company/kaziatx/) [](https://twitter.com/KaziaTx) [](https://www.youtube.com/channel/UCiovte4Ru7azEjm4pFaW2Xg)\n\nCopyright © 2024 Kazia Therapeutics Limited \n\n[Site Map](/site/utilities/site-map) [Privacy](/site/utilities/privacy) [Search](/site/utilities/site-map/search)\n\n[ Design byspatialdesign ](https://spatialdesign.com.au) [ Site by ![](/site/content/images/irm-logo-small-white.png) ](http://www.irmau.com)\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://www.kaziatherapeutics.com/site/for-investors/sec-filings",
          "content": "![](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n[![Kazia Therapeutics Limited](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)](/)\n\nHeading &\n\nSub-heading can be edited through HQI \n\n[ Home](/site/content/default.aspx) / [ For Investors](/site/for-investors) /[ SEC Filings](/site/for-investors/sec-filings)\n\n[](javascript:window.print\\(\\) \"Print Page\") [](# \"Font Smaller\") [](# \"Font Larger\")\n\n  * [Press Releases](/site/for-investors/press-releases)\n  * [ASX Announcements](/site/for-investors/asx-announcements)\n  * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n    * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n  * [SEC Filings](/site/for-investors/sec-filings)\n  * [Corporate Presentations](/site/for-investors/corporate-presentations)\n  * [Annual Reports](/site/for-investors/annual-reports)\n  * [ Financial Reports](/site/for-investors/financial-reports)\n  * [AGM](/site/for-investors/agm)\n  * [Corporate Governance](/site/for-investors/corporate-governance)\n  * [Shareholder Services](/site/for-investors/shareholder-services)\n\n\n\nShow All\n\nYear:  Filter by Year 20242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002\n\nFiling Type: Filter by Filing Type Current Reports Registration Statements\n\n1 2 3\n\n# SEC Filings\n\nContent coming soon. \n\n### Quick Links\n\n[Home](/site/content/)[About Us](/site/about-us1)[For Researchers](/site/for-researchers)[For Partners](/site/for-partners)[For Patients](/site/for-patients)[For Investors](/site/for-investors)[Media Centre](/site/media-centre)[Contact](/site/contact)\n\n### Contact Us\n\n**Kazia Therapeutics Limited** Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia  info@kaziatherapeutics.com [ https://www.kaziatherapeutics.com](https://www.kaziatherapeutics.com/)\n\n### Subscribe to Email Alerts\n\nASX Announcements\n\nMedia Releases & News\n\nWhich of the following group do you best fit?\n\nWhich of the following group do you best fit? Analyst Broker Financial Adviser Fund Manager Institutional Investor Sophisticated Investor Private Investor Media Representative General Interest\n\nYes No\n\n### Email Alerts\n\nSubscribe to our Email Alerts\n\n### Follow Us\n\n[](https://www.linkedin.com/company/kaziatx/) [](https://twitter.com/KaziaTx) [](https://www.youtube.com/channel/UCiovte4Ru7azEjm4pFaW2Xg)\n\nCopyright © 2024 Kazia Therapeutics Limited \n\n[Site Map](/site/utilities/site-map) [Privacy](/site/utilities/privacy) [Search](/site/utilities/site-map/search)\n\n[ Design byspatialdesign ](https://spatialdesign.com.au) [ Site by ![](/site/content/images/irm-logo-small-white.png) ](http://www.irmau.com)\n"
        }
      ]
    },
    {
      "section_name": "Corporate Presentations",
      "links": [
        {
          "title": "Corporate Presentations",
          "url": "https://www.kaziatherapeutics.com/site/for-investors/corporate-presentations",
          "content": "![](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n[![Kazia Therapeutics Limited](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)](/)\n\nHeading &\n\nSub-heading can be edited through HQI \n\n[ Home](/site/content/default.aspx) / [ For Investors](/site/for-investors) /[ Corporate Presentations](/site/for-investors/corporate-presentations)\n\n[](javascript:window.print\\(\\) \"Print Page\") [](# \"Font Smaller\") [](# \"Font Larger\")\n\n  * [Press Releases](/site/for-investors/press-releases)\n  * [ASX Announcements](/site/for-investors/asx-announcements)\n  * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n    * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n  * [SEC Filings](/site/for-investors/sec-filings)\n  * [Corporate Presentations](/site/for-investors/corporate-presentations)\n  * [Annual Reports](/site/for-investors/annual-reports)\n  * [ Financial Reports](/site/for-investors/financial-reports)\n  * [AGM](/site/for-investors/agm)\n  * [Corporate Governance](/site/for-investors/corporate-governance)\n  * [Shareholder Services](/site/for-investors/shareholder-services)\n\n\n\n# Corporate Presentations\n\nFilter by Year:[2024](/site/for-investors/corporate-presentations?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2024) [2023](/site/for-investors/corporate-presentations?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2023) [2022](/site/for-investors/corporate-presentations?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2022) [2021](/site/for-investors/corporate-presentations?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2021) [2020](/site/for-investors/corporate-presentations?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2020) [2019](/site/for-investors/corporate-presentations?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2019) [2018](/site/for-investors/corporate-presentations?Archive=True&ArchiveMonth=11&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2018)\n\n4-Nov-2024\n\n[Kazia Corporate Presentation November 2024](https://www.kaziatherapeutics.com:443/site/pdf/ebcc5b2e-29a6-410c-ab9a-c3e722413615/Kazia-Corporate-Presentation-November-2024.pdf)\n\n30-May-2024\n\n[Kazia Corporate Presentation May 2024](https://www.kaziatherapeutics.com:443/site/pdf/5e7ac8eb-9138-4efe-934f-f5a307f7a19a/Kazia-Corporate-Presentation-May-2024.pdf)\n\n12-Apr-2024\n\n[Kazia Corporate Presentation](https://www.kaziatherapeutics.com:443/site/pdf/5c0edf30-3754-4c47-b67f-c928ad36b676/Kazia-Corporate-Presentation.pdf)\n\n19-Mar-2024\n\n[EVT801 Progress Update Presentation](https://www.kaziatherapeutics.com:443/site/pdf/5c0efa93-b5cc-4d0d-9bcd-c9de9b65067f/EVT801-Progress-Update-Presentation.pdf)\n\n  * 1\n\n\n\n### Quick Links\n\n[Home](/site/content/)[About Us](/site/about-us1)[For Researchers](/site/for-researchers)[For Partners](/site/for-partners)[For Patients](/site/for-patients)[For Investors](/site/for-investors)[Media Centre](/site/media-centre)[Contact](/site/contact)\n\n### Contact Us\n\n**Kazia Therapeutics Limited** Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia  info@kaziatherapeutics.com [ https://www.kaziatherapeutics.com](https://www.kaziatherapeutics.com/)\n\n### Subscribe to Email Alerts\n\nASX Announcements\n\nMedia Releases & News\n\nWhich of the following group do you best fit?\n\nWhich of the following group do you best fit? Analyst Broker Financial Adviser Fund Manager Institutional Investor Sophisticated Investor Private Investor Media Representative General Interest\n\nYes No\n\n### Email Alerts\n\nSubscribe to our Email Alerts\n\n### Follow Us\n\n[](https://www.linkedin.com/company/kaziatx/) [](https://twitter.com/KaziaTx) [](https://www.youtube.com/channel/UCiovte4Ru7azEjm4pFaW2Xg)\n\nCopyright © 2024 Kazia Therapeutics Limited \n\n[Site Map](/site/utilities/site-map) [Privacy](/site/utilities/privacy) [Search](/site/utilities/site-map/search)\n\n[ Design byspatialdesign ](https://spatialdesign.com.au) [ Site by ![](/site/content/images/irm-logo-small-white.png) ](http://www.irmau.com)\n"
        }
      ]
    },
    {
      "section_name": "Annual Reports",
      "links": [
        {
          "title": "Annual Reports",
          "url": "https://www.kaziatherapeutics.com/site/for-investors/annual-reports",
          "content": "![](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n[![Kazia Therapeutics Limited](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)](/)\n\nHeading &\n\nSub-heading can be edited through HQI \n\n[ Home](/site/content/default.aspx) / [ For Investors](/site/for-investors) /[ Annual Reports](/site/for-investors/annual-reports)\n\n[](javascript:window.print\\(\\) \"Print Page\") [](# \"Font Smaller\") [](# \"Font Larger\")\n\n  * [Press Releases](/site/for-investors/press-releases)\n  * [ASX Announcements](/site/for-investors/asx-announcements)\n  * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n    * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n  * [SEC Filings](/site/for-investors/sec-filings)\n  * [Corporate Presentations](/site/for-investors/corporate-presentations)\n  * [Annual Reports](/site/for-investors/annual-reports)\n  * [ Financial Reports](/site/for-investors/financial-reports)\n  * [AGM](/site/for-investors/agm)\n  * [Corporate Governance](/site/for-investors/corporate-governance)\n  * [Shareholder Services](/site/for-investors/shareholder-services)\n\n\n\n# Annual Reports\n\n![](/site/file/115/AR2023.jpg)\n\n## Kazia Therapeutics Limited (ASX: KZA)\n\n### 2023 ANNUAL REPORT\n\n[VIEW REPORT](/site/content/AR/2023)\n\nFilter by Year:[2023](/site/for-investors/annual-reports?Archive=True&ArchiveMonth=8&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2023) [2022](/site/for-investors/annual-reports?Archive=True&ArchiveMonth=8&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2022) [2021](/site/for-investors/annual-reports?Archive=True&ArchiveMonth=8&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2021) [2020](/site/for-investors/annual-reports?Archive=True&ArchiveMonth=8&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2020) [2019](/site/for-investors/annual-reports?Archive=True&ArchiveMonth=8&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2019) [2018](/site/for-investors/annual-reports?Archive=True&ArchiveMonth=8&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2018) [2017](/site/for-investors/annual-reports?Archive=True&ArchiveMonth=8&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2023&FilterStyle=B&month=&DisplayType=E&year=2017)\n\n31-Aug-2023\n\n[Appendix 4E and 2023 Annual Report](https://www.kaziatherapeutics.com:443/site/pdf/559cac84-ba5e-4fb3-8e3f-95b3eeea5cf8/Appendix-4E-and-2023-Annual-Report.pdf)\n\n  * 1\n\n\n\n### Quick Links\n\n[Home](/site/content/)[About Us](/site/about-us1)[For Researchers](/site/for-researchers)[For Partners](/site/for-partners)[For Patients](/site/for-patients)[For Investors](/site/for-investors)[Media Centre](/site/media-centre)[Contact](/site/contact)\n\n### Contact Us\n\n**Kazia Therapeutics Limited** Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia  info@kaziatherapeutics.com [ https://www.kaziatherapeutics.com](https://www.kaziatherapeutics.com/)\n\n### Subscribe to Email Alerts\n\nASX Announcements\n\nMedia Releases & News\n\nWhich of the following group do you best fit?\n\nWhich of the following group do you best fit? Analyst Broker Financial Adviser Fund Manager Institutional Investor Sophisticated Investor Private Investor Media Representative General Interest\n\nYes No\n\n### Email Alerts\n\nSubscribe to our Email Alerts\n\n### Follow Us\n\n[](https://www.linkedin.com/company/kaziatx/) [](https://twitter.com/KaziaTx) [](https://www.youtube.com/channel/UCiovte4Ru7azEjm4pFaW2Xg)\n\nCopyright © 2024 Kazia Therapeutics Limited \n\n[Site Map](/site/utilities/site-map) [Privacy](/site/utilities/privacy) [Search](/site/utilities/site-map/search)\n\n[ Design byspatialdesign ](https://spatialdesign.com.au) [ Site by ![](/site/content/images/irm-logo-small-white.png) ](http://www.irmau.com)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Financial Reports",
          "url": "https://www.kaziatherapeutics.com/site/for-investors/financial-reports",
          "content": "![](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n[![Kazia Therapeutics Limited](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)](/)\n\nHeading &\n\nSub-heading can be edited through HQI \n\n[ Home](/site/content/default.aspx) / [ For Investors](/site/for-investors) /[ Financial Reports](/site/for-investors/financial-reports)\n\n[](javascript:window.print\\(\\) \"Print Page\") [](# \"Font Smaller\") [](# \"Font Larger\")\n\n  * [Press Releases](/site/for-investors/press-releases)\n  * [ASX Announcements](/site/for-investors/asx-announcements)\n  * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n    * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n  * [SEC Filings](/site/for-investors/sec-filings)\n  * [Corporate Presentations](/site/for-investors/corporate-presentations)\n  * [Annual Reports](/site/for-investors/annual-reports)\n  * [ Financial Reports](/site/for-investors/financial-reports)\n  * [AGM](/site/for-investors/agm)\n  * [Corporate Governance](/site/for-investors/corporate-governance)\n  * [Shareholder Services](/site/for-investors/shareholder-services)\n\n\n\n#  Financial Reports\n\nFilter by Year:[2024](/site/for-investors/financial-reports?Archive=True&ArchiveMonth=3&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2024) [2023](/site/for-investors/financial-reports?Archive=True&ArchiveMonth=3&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2023) [2022](/site/for-investors/financial-reports?Archive=True&ArchiveMonth=3&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2022) [2021](/site/for-investors/financial-reports?Archive=True&ArchiveMonth=3&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2021) [2020](/site/for-investors/financial-reports?Archive=True&ArchiveMonth=3&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2020) [2019](/site/for-investors/financial-reports?Archive=True&ArchiveMonth=3&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2019) [2018](/site/for-investors/financial-reports?Archive=True&ArchiveMonth=3&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2018) [2017](/site/for-investors/financial-reports?Archive=True&ArchiveMonth=3&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=2017) [Older](/site/for-investors/financial-reports?Archive=True&ArchiveMonth=3&ArchiveQuarter=Q4&Archive6Mths=H2&ArchiveYear=2024&FilterStyle=B&month=&DisplayType=E&year=older2016)\n\n27-Mar-2024\n\n[Half Yearly Report and Accounts](https://www.kaziatherapeutics.com:443/site/pdf/940bce02-0340-4fb5-99c3-50ad75f85338/Half-Yearly-Report-and-Accounts.pdf)\n\n  * 1\n\n\n\n### Quick Links\n\n[Home](/site/content/)[About Us](/site/about-us1)[For Researchers](/site/for-researchers)[For Partners](/site/for-partners)[For Patients](/site/for-patients)[For Investors](/site/for-investors)[Media Centre](/site/media-centre)[Contact](/site/contact)\n\n### Contact Us\n\n**Kazia Therapeutics Limited** Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia  info@kaziatherapeutics.com [ https://www.kaziatherapeutics.com](https://www.kaziatherapeutics.com/)\n\n### Subscribe to Email Alerts\n\nASX Announcements\n\nMedia Releases & News\n\nWhich of the following group do you best fit?\n\nWhich of the following group do you best fit? Analyst Broker Financial Adviser Fund Manager Institutional Investor Sophisticated Investor Private Investor Media Representative General Interest\n\nYes No\n\n### Email Alerts\n\nSubscribe to our Email Alerts\n\n### Follow Us\n\n[](https://www.linkedin.com/company/kaziatx/) [](https://twitter.com/KaziaTx) [](https://www.youtube.com/channel/UCiovte4Ru7azEjm4pFaW2Xg)\n\nCopyright © 2024 Kazia Therapeutics Limited \n\n[Site Map](/site/utilities/site-map) [Privacy](/site/utilities/privacy) [Search](/site/utilities/site-map/search)\n\n[ Design byspatialdesign ](https://spatialdesign.com.au) [ Site by ![](/site/content/images/irm-logo-small-white.png) ](http://www.irmau.com)\n"
        }
      ]
    },
    {
      "section_name": "AGM",
      "links": [
        {
          "title": "AGM",
          "url": "https://www.kaziatherapeutics.com/site/for-investors/agm",
          "content": "![](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n[![Kazia Therapeutics Limited](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)](/)\n\nHeading &\n\nSub-heading can be edited through HQI \n\n[ Home](/site/content/default.aspx) / [ For Investors](/site/for-investors) /[ AGM](/site/for-investors/agm)\n\n[](javascript:window.print\\(\\) \"Print Page\") [](# \"Font Smaller\") [](# \"Font Larger\")\n\n  * [Press Releases](/site/for-investors/press-releases)\n  * [ASX Announcements](/site/for-investors/asx-announcements)\n  * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n    * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n  * [SEC Filings](/site/for-investors/sec-filings)\n  * [Corporate Presentations](/site/for-investors/corporate-presentations)\n  * [Annual Reports](/site/for-investors/annual-reports)\n  * [ Financial Reports](/site/for-investors/financial-reports)\n  * [AGM](/site/for-investors/agm)\n  * [Corporate Governance](/site/for-investors/corporate-governance)\n  * [Shareholder Services](/site/for-investors/shareholder-services)\n\n\n\n# AGM\n\n### Access AGM Presentation\n\n## Kazia Therapeutics Annual General Meeting\n\nKazia's 2023 AGM will be held as a virtual meeting on Thursday 30 November 2023.More information [here](/site/pdf/bb537957-d9a4-42d8-b3d4-5951374427f7/Notice-of-Annual-General-MeetingProxy-Form.pdf).\n\n![](/site/file/114/AR2023KZA.jpg)\n\n### Annual Report\n\n[View Report](/site/content/AR/2023)\n\n![](/site/media/88/chair_address.png)\n\n### Chairman’s Address & Presentation\n\n[View Report](/site/pdf/4c110061-253b-442b-82fe-4e5e6c2db373/AGM-2023-Chairmans-Address.pdf)\n\n![](/site/media/89/clinical.png)\n\n### 2023 AGM Presentation\n\n[View Report](/site/pdf/c251b254-3aba-49f5-9094-429ecaab94b7/AGM-Clinical-Slides.pdf)\n\n![](/site/media/90/results-meeting.png)\n\n### AGM Results of Meeting\n\n[View Report](/site/pdf/c50191b2-e45e-41b9-a5cd-477a0d427cda/AGM-Final-Meeting-Results.pdf)\n\n### Annual General Meeting Outline\n\n  1. Adoption of Remuneration Report;\n  2. Re-Election of Steven Coffey;\n  3. The grant of up to 3,500,000 Options to Dr James Garner;\n  4. The ratification of prior issue of ATM Shares;\n  5. Approval of Additional Placement capacity under Listing Rule 7.1A;\n  6. Adoption of New Constitution; and\n  7. Approval of Proportional Takeover Provisions.\n\n\n\n### AGM Announcements\n\n[Read More](/site/for-investors/agm-page/agm-announcements)\n\nEmail Alerts\n\n[](/site/contact/email-alerts)\n\nFor Investors\n\n[](/site/for-investors)\n\nContact Us\n\n[](/site/contact/contact-us)\n\n### Quick Links\n\n[Home](/site/content/)[About Us](/site/about-us1)[For Researchers](/site/for-researchers)[For Partners](/site/for-partners)[For Patients](/site/for-patients)[For Investors](/site/for-investors)[Media Centre](/site/media-centre)[Contact](/site/contact)\n\n### Contact Us\n\n**Kazia Therapeutics Limited** Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia  info@kaziatherapeutics.com [ https://www.kaziatherapeutics.com](https://www.kaziatherapeutics.com/)\n\n### Subscribe to Email Alerts\n\nASX Announcements\n\nMedia Releases & News\n\nWhich of the following group do you best fit?\n\nWhich of the following group do you best fit? Analyst Broker Financial Adviser Fund Manager Institutional Investor Sophisticated Investor Private Investor Media Representative General Interest\n\nYes No\n\n### Email Alerts\n\nSubscribe to our Email Alerts\n\n### Follow Us\n\n[](https://www.linkedin.com/company/kaziatx/) [](https://twitter.com/KaziaTx) [](https://www.youtube.com/channel/UCiovte4Ru7azEjm4pFaW2Xg)\n\nCopyright © 2024 Kazia Therapeutics Limited \n\n[Site Map](/site/utilities/site-map) [Privacy](/site/utilities/privacy) [Search](/site/utilities/site-map/search)\n\n[ Design byspatialdesign ](https://spatialdesign.com.au) [ Site by ![](/site/content/images/irm-logo-small-white.png) ](http://www.irmau.com)\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Corporate Governance",
          "url": "https://www.kaziatherapeutics.com/site/for-investors/corporate-governance",
          "content": "![](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n[![Kazia Therapeutics Limited](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)](/)\n\nHeading &\n\nSub-heading can be edited through HQI \n\n[ Home](/site/content/default.aspx) / [ For Investors](/site/for-investors) /[ Corporate Governance](/site/for-investors/corporate-governance)\n\n[](javascript:window.print\\(\\) \"Print Page\") [](# \"Font Smaller\") [](# \"Font Larger\")\n\n  * [Press Releases](/site/for-investors/press-releases)\n  * [ASX Announcements](/site/for-investors/asx-announcements)\n  * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n    * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n  * [SEC Filings](/site/for-investors/sec-filings)\n  * [Corporate Presentations](/site/for-investors/corporate-presentations)\n  * [Annual Reports](/site/for-investors/annual-reports)\n  * [ Financial Reports](/site/for-investors/financial-reports)\n  * [AGM](/site/for-investors/agm)\n  * [Corporate Governance](/site/for-investors/corporate-governance)\n  * [Shareholder Services](/site/for-investors/shareholder-services)\n\n\n\n# Corporate Governance\n\nKazia Therapeutics follows the highest standards of corporate governance so as to drive sustainable, long-term shareholder value while recognising our broader obligations to a wide range of stakeholders.\n\n[Board Charter](/site/file/2/view/210224_Board_Charter.pdf)\n\n[](/site/file/2/view/210224_Board_Charter.pdf)\n\n[Whistleblower Policy](/site/file/4/view/210224_Whistleblower_policy.pdf)\n\n[Securities Trading Policy](/site/file/5/view/210224_Securities_trading_policy.pdf)\n\n[Anti-Corruption Compliance Policy](/site/file/6/view/210224_Anticorruption_compliance_policy.pdf)\n\n[Employee Share Option Plan](/site/PDF/8fe1931b-9e1b-49bd-b286-3e661cc4fe2a/EmployeeShareOptionPlan)\n\n[Corporate Governance Statement](/site/pdf/c85d0164-e2e0-4db0-88a0-25535d184fb2/220829-Corporate-governance-statement-FY2022.pdf)\n\n[Expanded Access Policy](/site/file/9/view/200902_Expanded_Access_Policy.pdf)\n\n[Value Statement](/site/file/10/view/200219_Kazia_Values_Statement.pdf)\n\n[Audit Risk and Governance Charter](/site/PDF/f0ef3a45-e26c-4036-8082-9e79a7d8c1a2/210310AuditRiskandGovernanceCommitteeCharter)\n\n[Remuneration and Nominations Charter](/site/PDF/c8dbfc2a-65ee-4f19-91d6-84ce8fc610bb/210310RemunerationandNominationsCommitteeCharter)\n\n[Code of Business Conduct and Ethics](/site/PDF/35ebefd0-0af4-406a-9984-3687d6d39e9b/220518CodeofBusinessConductandEthics)\n\n[Continuous Disclosure](/site/file/14/view/190828_Continuous_disclosure_policy.pdf)\n\n[Shareholder Communications](/site/pdf/4489f945-b4bd-4817-815b-407a46f10b2b/Shareholder-Communications-Policy.pdf)\n\n[Constitution](/site/pdf/59282ba9-4aa3-44cf-b2a2-43e5e01f061c/Constitution.pdf)\n\n[Board Skill Matrix](/site/pdf/9d23fdef-d878-40cb-b530-fabe53f209f5/220824-Board-Skills-Matrix.pdf)\n\n### Quick Links\n\n[Home](/site/content/)[About Us](/site/about-us1)[For Researchers](/site/for-researchers)[For Partners](/site/for-partners)[For Patients](/site/for-patients)[For Investors](/site/for-investors)[Media Centre](/site/media-centre)[Contact](/site/contact)\n\n### Contact Us\n\n**Kazia Therapeutics Limited** Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia  info@kaziatherapeutics.com [ https://www.kaziatherapeutics.com](https://www.kaziatherapeutics.com/)\n\n### Subscribe to Email Alerts\n\nASX Announcements\n\nMedia Releases & News\n\nWhich of the following group do you best fit?\n\nWhich of the following group do you best fit? Analyst Broker Financial Adviser Fund Manager Institutional Investor Sophisticated Investor Private Investor Media Representative General Interest\n\nYes No\n\n### Email Alerts\n\nSubscribe to our Email Alerts\n\n### Follow Us\n\n[](https://www.linkedin.com/company/kaziatx/) [](https://twitter.com/KaziaTx) [](https://www.youtube.com/channel/UCiovte4Ru7azEjm4pFaW2Xg)\n\nCopyright © 2024 Kazia Therapeutics Limited \n\n[Site Map](/site/utilities/site-map) [Privacy](/site/utilities/privacy) [Search](/site/utilities/site-map/search)\n\n[ Design byspatialdesign ](https://spatialdesign.com.au) [ Site by ![](/site/content/images/irm-logo-small-white.png) ](http://www.irmau.com)\n"
        }
      ]
    },
    {
      "section_name": "Shareholder Services",
      "links": [
        {
          "title": "Shareholder Services",
          "url": "https://www.kaziatherapeutics.com/site/for-investors/shareholder-services",
          "content": "![](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n  * [Home](/site/content/)\n  * [About Us](/site/about-us1)\n    * [About Us](/site/about-us1/about-us)\n    * [Board of Directors](/site/about-us1/board-of-directors)\n    * [Scientific Advisory Board](/site/about-us1/scientific-advisory-board)\n    * [Management Team](/site/about-us1/management-team)\n    * [Careers ](/site/about-us1/careers)\n  * [For Researchers](/site/for-researchers)\n    * [Paxalisib](/site/for-researchers/paxalisib)\n    * [EVT801](/site/for-researchers/evt801)\n    * [Collaborating with Kazia](/site/for-researchers/collaborating-with-kazia)\n    * [Publications and Presentations](/site/for-researchers/publications-and-presentations)\n  * [For Partners](/site/for-partners)\n    * [Our Current Partners](/site/for-partners/our-current-partners)\n    * [What We Are Looking For](/site/for-partners/what-we-are-looking-for)\n  * [For Patients](/site/for-patients)\n    * [Accessing Kazia Drug Candidates in Clinical Trials](/site/for-patients/accessing-kazia-drug-candidates-in-clinical-trials)\n    * [Accessing Kazia Drug Candidates for Compassionate Use](/site/for-patients/accessing-kazia-drug-candidates-for-compassionate-use)\n    * [Resources for Patients](/site/for-patients/resources-for-patients)\n  * [For Investors](/site/for-investors)\n    * [Press Releases](/site/for-investors/press-releases)\n    * [ASX Announcements](/site/for-investors/asx-announcements)\n    * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n      * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n    * [SEC Filings](/site/for-investors/sec-filings)\n    * [Corporate Presentations](/site/for-investors/corporate-presentations)\n    * [Annual Reports](/site/for-investors/annual-reports)\n    * [ Financial Reports](/site/for-investors/financial-reports)\n    * [AGM](/site/for-investors/agm)\n    * [Corporate Governance](/site/for-investors/corporate-governance)\n    * [Shareholder Services](/site/for-investors/shareholder-services)\n  * [Media Centre](/site/media-centre)\n    * [Overview](/site/media-centre/overview)\n    * [Video](/site/media-centre/video)\n    * [Coverage](/site/media-centre/coverage)\n  * [Contact](/site/contact)\n    * [Contact Us](/site/contact/contact-us)\n    * [Subscribe to email alerts](/site/contact/email-alerts)\n\n\n\n[![Kazia Therapeutics Limited](https://www.kaziatherapeutics.com/site/irmpreference/1277/kzalogo.png)](/)\n\nHeading &\n\nSub-heading can be edited through HQI \n\n[ Home](/site/content/default.aspx) / [ For Investors](/site/for-investors) /[ Shareholder Services](/site/for-investors/shareholder-services)\n\n[](javascript:window.print\\(\\) \"Print Page\") [](# \"Font Smaller\") [](# \"Font Larger\")\n\n  * [Press Releases](/site/for-investors/press-releases)\n  * [ASX Announcements](/site/for-investors/asx-announcements)\n  * [Delisting from ASX](/site/for-investors/delisting-from-asx)\n    * [How to convert unlisted shares to ADSs](/site/for-investors/delisting-from-asx/how-to-convert-unlisted-shares-to-adss)\n  * [SEC Filings](/site/for-investors/sec-filings)\n  * [Corporate Presentations](/site/for-investors/corporate-presentations)\n  * [Annual Reports](/site/for-investors/annual-reports)\n  * [ Financial Reports](/site/for-investors/financial-reports)\n  * [AGM](/site/for-investors/agm)\n  * [Corporate Governance](/site/for-investors/corporate-governance)\n  * [Shareholder Services](/site/for-investors/shareholder-services)\n\n\n\n# Shareholder Services\n\n#### **Computershare Investor Services Pty Limited**\n\nLevel 4, 60 Carrington StreetSydney, NSWAustralia, 2000Phone: [1300 787 272](tel:1300%20787 272)\n\nInvestor Centre Access:<https://www-au.computershare.com/Investor/>\n\nIn this section, Shareholders are able to link through to the Company's share registry, Computershare, and perform the following tasks:\n\n**View your security holdings**\n\nCheck your account details; see your holding balance or change your communication preferences.\n\nClick[here](https://www-au.computershare.com/Investor/) to view your security holdings.\n\n**Change your shareholding records**\n\nThis section of the website is designed to provide you with the forms necessary to initiate any changes to the details held on the Company's shareholder records with Computershare.\n\nClick[here](https://www-au.computershare.com/Investor/)to view a full list of downloadable assets.\n\nFor any further questions regarding your holding please contact Computershare Investor Services.\n\n**Communications Preferences Update** Recent legislative changes to the Corporations Act 2001 (Cth) effective 1 April 2022 means there are new options available to you as a securityholder as to how you elect to receive your communications. Kazia will no longer send physical meeting documents to you unless you request a copy to be mailed.We encourage you to provide an email address so that we can communicate with you electronically when shareholder notices become available online, for such items as meeting documents, dividend statements and annual reports. You can make a standing election or an ad hoc request to receive, or not to receive, some or all of your securityholder communications in physical or electronic form.To review or update your current communications preference, please update your details via our Share Registry’s website via their [Investor Centre](https://www-au.computershare.com/Investor/). You will need your Security Reference Number (SRN) or Holder Identification Number (HIN) and your postcode to verify your identity.\n\n### Quick Links\n\n[Home](/site/content/)[About Us](/site/about-us1)[For Researchers](/site/for-researchers)[For Partners](/site/for-partners)[For Patients](/site/for-patients)[For Investors](/site/for-investors)[Media Centre](/site/media-centre)[Contact](/site/contact)\n\n### Contact Us\n\n**Kazia Therapeutics Limited** Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia  info@kaziatherapeutics.com [ https://www.kaziatherapeutics.com](https://www.kaziatherapeutics.com/)\n\n### Subscribe to Email Alerts\n\nASX Announcements\n\nMedia Releases & News\n\nWhich of the following group do you best fit?\n\nWhich of the following group do you best fit? Analyst Broker Financial Adviser Fund Manager Institutional Investor Sophisticated Investor Private Investor Media Representative General Interest\n\nYes No\n\n### Email Alerts\n\nSubscribe to our Email Alerts\n\n### Follow Us\n\n[](https://www.linkedin.com/company/kaziatx/) [](https://twitter.com/KaziaTx) [](https://www.youtube.com/channel/UCiovte4Ru7azEjm4pFaW2Xg)\n\nCopyright © 2024 Kazia Therapeutics Limited \n\n[Site Map](/site/utilities/site-map) [Privacy](/site/utilities/privacy) [Search](/site/utilities/site-map/search)\n\n[ Design byspatialdesign ](https://spatialdesign.com.au) [ Site by ![](/site/content/images/irm-logo-small-white.png) ](http://www.irmau.com)\n"
        }
      ]
    }
  ]
}